Literature DB >> 17016805

Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study.

Zhiyong Xie1, Qiongfeng Liao, Xinjun Xu, Meicun Yao, Jinzhi Wan, Dan Liu.   

Abstract

A liquid chromatography/tandem mass spectrometry (LC/MS/MS) method was developed and validated for the determination of donepezil in human plasma samples. Diphenhydramine was used as the internal standard. The collision-induced transition m/z 380 --> 91 was used to analyze donepezil in selected reaction monitoring mode. The signal intensity of the m/z 380 --> 91 transition was found to relate linearly with donepezil concentrations in plasma from 0.1-20.0 ng/mL. The lower limit of quantification of the LC/MS/MS method was 0.1 ng/mL. The intra- and inter-day precisions were below 10.2% and the accuracy was between -2.3% and +2.8%. The validated LC/MS/MS method was applied to a pharmacokinetic study in which healthy Chinese volunteers each received a single oral dose of 5 mg donepezil hydrochloride. The non-compartmental pharmacokinetic model was used to fit the donepezil plasma concentration-time curve. Maximum plasma concentration was 12.3 +/- 2.73 ng/mL which occurred at 3.50 +/- 1.61 h post-dosing. The apparent elimination half-life and the area under the curve were, respectively, 60.86 +/- 12.05 h and 609.3 +/- 122.2 ng . h/mL. LC/MS/MS is a rapid, sensitive and specific method for determining donepezil in human plasma samples. Copyright (c) 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17016805     DOI: 10.1002/rcm.2718

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  3 in total

1.  Ultrafast liquid chromatography-tandem mass spectrometry determination of donepezil in human plasma: application to a bioequivalence study.

Authors:  Yan-Wen Huang; Li Ding; Yuan-Ming Chen; Wei-Chen Lin; Fei Lin; Yunsheng Hsieh
Journal:  Transl Clin Pharmacol       Date:  2022-02-24

2.  Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer's disease and vascular dementia.

Authors:  Thitipon Yaowaluk; Vorapun Senanarong; Chanin Limwongse; Rasda Boonprasert; Pornpimol Kijsanayotin
Journal:  Pharmgenomics Pers Med       Date:  2019-09-04

3.  CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia.

Authors:  Monpat Chamnanphon; Sorawit Wainipitapong; Teeravut Wiwattarangkul; Phenphichcha Chuchuen; Kunathip Nissaipan; Weeraya Phaisal; Sookjaroen Tangwongchai; Chonlaphat Sukasem; Supeecha Wittayalertpanya; Andrea Gaedigk; Daruj Aniwattanapong; Pajaree Chariyavilaskul
Journal:  Pharmgenomics Pers Med       Date:  2020-11-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.